Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
A persistent infection with human papillomavirus (HPV) is a prerequisite for the development of cervical cancer. Clinical trials with HPV-vaccines have been very successful in preventing persistent HPV16/18 infections, the two most oncogenic HPV-genotypes. We assessed the introduction of universal HPV-vaccination for preadolescent girls in the Dutch National Immunization Programme. Long-term vaccine efficacy, the need and extent of a catch-up programme for young women, and the impact of vaccination on the cervical cancer screening programme are major unresolved issues. Preliminary conservative estimates (80% vaccine efficacy and no effects on the screening programme, transmission rate, non-cervical cancer incidence, and cross protection) predict an acceptable cost-effectiveness ratio for universal vaccination of preadolescent girls.
Boot
Hein J
HJ
Laboratory for Infectious Diseases and Perinatal Screening, RIVM, Bilthoven, The Netherlands. hein.boot@rivm.nl
Wallenburg
Iris
I
de Melker
Hester E
HE
Mangen
Marie-José M
MJ
Gerritsen
Annette A M
AA
van der Maas
Nicoline A
NA
Berkhof
Johannes
J
Meijer
Chris J L M
CJ
Kimman
Tjeerd G
TG
D017677:Age Distribution; D002648:Child; D003075:Coitus; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D009426:Netherlands / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*; D011788:Quality of Life; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology
D053918:Papillomavirus Vaccines